Keith W Pfeil
CIK 1752014 · View on SEC EDGAR ↗
First SEC filing: Aug. 26, 2019 · Latest: Aug. 26, 2019
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Jan. 10, 2025 | GMED | S 10b5-1 | 1,666 | $89.17 | $148,557 | 0 Direct | -100.00% | Disposed | -1.0% (price as of 2026-08-19) |
| Jan. 10, 2025 | GMED | S 10b5-1 | 12,501 | $88.17 | $1,102,213 | 1,666 Direct | -88.24% | Disposed | 0.1% (price as of 2026-08-19) |
| Feb. 2, 2023 | GMED | S 10b5-1 | 29,167 | $77.57 | $2,262,484 | 0 Direct | -100.00% | Disposed | 13.8% (price as of 2026-08-19) |
| Aug. 19, 2021 | GMED | S 10b5-1 | 833 | $76.13 | $63,416 | 0 Direct | -100.00% | Disposed | 15.9% (price as of 2026-08-19) |
| Aug. 19, 2021 | GMED | S 10b5-1 | 833 | $76.13 | $63,416 | 0 Direct | -100.00% | Disposed | 15.9% (price as of 2026-08-19) |
| Aug. 2, 2021 | GMED | S 10b5-1 | 833 | $83.24 | $69,339 | 0 Direct | -100.00% | Disposed | 6.0% (price as of 2026-08-19) |
| July 19, 2021 | GMED | S 10b5-1 | 834 | $78.25 | $65,260 | 0 Direct | -100.00% | Disposed | 12.8% (price as of 2026-08-19) |
| July 1, 2021 | GMED | S 10b5-1 | 833 | $77.43 | $64,499 | 0 Direct | -100.00% | Disposed | 14.0% (price as of 2026-08-19) |
| June 25, 2021 | GMED | S 10b5-1 | 27,479 | $75.04 | $2,062,024 | 0 Direct | -100.00% | Disposed | 17.6% (price as of 2026-08-19) |
| May 5, 2021 | GMED | S 10b5-1 | 5,021 | $75.00 | $376,575 | 0 Direct | -100.00% | Disposed | 17.7% (price as of 2026-08-19) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Jan. 21, 2026 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (100,000) | $94.15 | Jan. 21, 2036 | 100,000 | Acquired |
| July 18, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (40,000) | $56.34 | July 18, 2035 | 40,000 | Acquired |
| Jan. 23, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (60,000) | $92.42 | Jan. 23, 2035 | 60,000 | Acquired |
| Jan. 10, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (8,334) | $53.27 | Jan. 22, 2030 | 8,334 | Disposed |
| Jan. 10, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (5,833) | $49.65 | Sept. 3, 2029 | 5,833 | Disposed |
| Jan. 26, 2024 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (60,000) | $53.75 | Jan. 26, 2034 | 60,000 | Acquired |
| Oct. 10, 2023 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (5,000) | $53.02 | Sept. 1, 2033 | 5,000 | Acquired |
| Feb. 2, 2023 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (15,000) | $53.27 | Jan. 22, 2030 | 15,000 | Disposed |
| Feb. 2, 2023 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (14,167) | $49.65 | Sept. 3, 2029 | 14,167 | Disposed |
| Jan. 26, 2023 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (40,000) | $75.18 | Jan. 26, 2033 | 40,000 | Acquired |
| Jan. 27, 2022 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (40,000) | $63.68 | Jan. 27, 2032 | 40,000 | Acquired |
| Aug. 19, 2021 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (0) | $53.27 | Jan. 22, 2030 | 0 | Disposed |
| Aug. 19, 2021 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (833) | — | Sept. 3, 2029 | 833 | Disposed |
| Aug. 19, 2021 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (833) | $53.27 | Jan. 22, 2030 | 833 | Disposed |
| Aug. 2, 2021 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (833) | $53.27 | Jan. 22, 2030 | 833 | Disposed |
| July 19, 2021 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (834) | $49.65 | Sept. 3, 2029 | 834 | Disposed |
| July 1, 2021 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (833) | $53.27 | Jan. 22, 2030 | 833 | Disposed |
| June 25, 2021 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (14,167) | $53.27 | Jan. 22, 2030 | 14,167 | Disposed |
| June 25, 2021 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (13,312) | $49.65 | Sept. 3, 2029 | 13,312 | Disposed |
| May 5, 2021 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (5,021) | $49.65 | Sept. 3, 2029 | 5,021 | Disposed |
| Jan. 14, 2021 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (40,000) | $65.05 | Jan. 14, 2031 | 40,000 | Acquired |
| Jan. 22, 2020 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (40,000) | $53.27 | Jan. 22, 2030 | 40,000 | Acquired |
| Sept. 3, 2019 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (40,000) | $49.65 | Sept. 3, 2029 | 40,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 1 holding
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Aug. 26, 2019 | GMED | No securities are beneficially owned | 0 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
GMED
CEO| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2025 | $479,467 | $117,000 | — | — | $783,000 | — | $38,345 | $4,400,159 |
| 2024 | $463,555 | — | — | $1,258,665 | $605,454 | — | $35,604 | $2,363,278 |
| 2023 | $414,690 | $100,000 | — | $1,179,403 | $336,375 | — | $32,980 | $2,063,448 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.